An anti-TL1A antibody for the treatment of asthma and inflammatory bowel disease

TL1A is an attractive therapeutic target for the treatment of mucosal inflammation associated with inflammatory bowel disease (IBD) and asthma. Blockade of the TL1A pathway has been shown to reduce inflammatory responses while leaving baseline immunity intact, and to be beneficial in animal models o...

Descripción completa

Detalles Bibliográficos
Autores principales: Clarke, Adam W., Poulton, Lynn, Shim, Doris, Mabon, David, Butt, Danyal, Pollard, Matthew, Pande, Vanya, Husten, Jean, Lyons, Jacquelyn, Tian, Chen, Doyle, Anthony G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2018
Materias:
Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5973687/
https://www.ncbi.nlm.nih.gov/pubmed/29436901
http://dx.doi.org/10.1080/19420862.2018.1440164

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5973687/
https://www.ncbi.nlm.nih.gov/pubmed/29436901
http://dx.doi.org/10.1080/19420862.2018.1440164

Ejemplares similares